AbbVie concedes another PhIII cancer drug flop as glioblastoma defeats latest assault
One of AbbVie’s top late-stage cancer drugs has flopped in a pivotal trial — the latest victim to hit bottom in the face of glioblastoma.
The pharma giant $ABBV noted Friday morning that depatuxizumab mafodotin (or depatux-m; previously known as ABT-414) has been failing to spark a survival benefit in EGFR-amplified cases of the common form of brain cancer in a Phase III study, causing the independent monitors to call it off for the antibody-drug conjugate.
Andrew LassmanThis had been one of AbbVie’s leading late-stage assets in oncology, alongside the bitterly disappointing Rova-T, which has experienced a series of setbacks. AbbVie has had considerable success in cancer with its commercial products and has seen advances with its anti-inflammatories as well. But they took on a tough target when they went after glioblastoma.
Basic subscription required
Unlock this story instantly and join 53,400+ biopharma pros reading Endpoints daily — and it's free.